Carregant...
Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
BACKGROUND: Sodium‐glucose cotransporter (SGLT) 2 inhibitors were recently approved as glucose‐lowering interventions in people with type 2 diabetes mellitus (T2DM). Potential beneficial or harmful effects of SGLT 2 inhibitors in people at risk for the development of T2DM are unknown. OBJECTIVES: To...
Guardat en:
| Publicat a: | Cochrane Database Syst Rev |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
2016
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486006/ https://ncbi.nlm.nih.gov/pubmed/27101360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012106.pub2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|